These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32983144)

  • 41. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
    Shizuru JA; Jerabek L; Edwards CT; Weissman IL
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):3-14. PubMed ID: 9078349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
    van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
    Front Immunol; 2018; 9():3016. PubMed ID: 30619360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
    Huang W; Chao NJ
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):211-219. PubMed ID: 28636890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and serological characterization of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.
    Yang Z; Wu B; Zhou Y; Wang W; Chen S; Sun A; Wu D; Xu Y
    Chin Med J (Engl); 2014; 127(7):1235-8. PubMed ID: 24709172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.
    Riddell SR; Berger C; Murata M; Randolph S; Warren EH
    Blood Rev; 2003 Sep; 17(3):153-62. PubMed ID: 12818225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
    Raj K; Narayanan S; Augustson B; Ho A; Mehta P; Duncan N; Tauro S; Mahendra P; Craddock C; Mufti G
    Bone Marrow Transplant; 2005 Feb; 35(3):299-301. PubMed ID: 15568036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A mixed-type autoimmune hemolytic anemia with immune thrombocytopenia related with myositis and post-transplantation lymphoproliferative disorder.
    Ogura M; Ichikawa M; Masuda A; Kandabashi K; Nannya Y; Kurokawa M
    Ann Hematol; 2014 May; 93(5):869-71. PubMed ID: 24013519
    [No Abstract]   [Full Text] [Related]  

  • 48. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decrease of CD4(+)CD25(+) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation.
    Li Q; Zhai Z; Xu X; Shen Y; Zhang A; Sun Z; Liu H; Geng L; Wang Y
    Leuk Res; 2010 Sep; 34(9):1158-68. PubMed ID: 20409584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease.
    Sevilla J; González-Vicent M; Madero L; Díaz MA
    Bone Marrow Transplant; 2001 Jul; 28(1):89-92. PubMed ID: 11498750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
    Kordelas L; Schwich E; Lindemann M; Heinemann FM; Buttkereit U; Horn PA; Beelen DW; Rebmann V
    Front Immunol; 2019; 10():3027. PubMed ID: 31998310
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders.
    Bhatt ST; Bednarski JJ
    Front Immunol; 2020; 11():1988. PubMed ID: 33013851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.
    Toor AA; Sabo RT; Roberts CH; Moore BL; Salman SR; Scalora AF; Aziz MT; Shubar Ali AS; Hall CE; Meier J; Thorn RM; Wang E; Song S; Miller K; Rizzo K; Clark WB; McCarty JM; Chung HM; Manjili MH; Neale MC
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1237-45. PubMed ID: 25849208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Reconstitution kinetics of dendritic cells following allogeneic hematopoietic stem cell transplantation].
    Fu HX; Zhang XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):222-6. PubMed ID: 18315936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.